http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106589129-B
Outgoing Links
Predicate | Object |
---|---|
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-468 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
filingDate | 2016-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2021-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2021-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CN-106589129-B |
titleOfInvention | Tri-functional molecule combined with CD19, CD3 and CD28 and application thereof |
abstract | The invention belongs to the technical field of biological medicines, and particularly relates to a tri-functional molecule combined with CD19, CD3 and CD28 and application thereof. The invention constructs three functional molecules capable of simultaneously recognizing CD19, CD3 and CD28 by using methods of genetic engineering and antibody engineering. The molecule has obvious advantages in the aspects of preparation process and practical application: the targeting effect of the T cells to CD19 positive cells is endowed, the efficacy of activating the T cells is further improved, the mediated combination and killing effect of the T cells to the CD19 positive target cells when the T cells are added independently are better than that of an anti-CD 19/anti-CD 3BiTE bispecific antibody, and the application convenience is better than that of a CD19 targeted CAR-T technology. |
priorityDate | 2016-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 522.